NEW YORK (AP) — All of 23andMe's independent directors resigned from its board this week, a rare move that marks the latest ...

Adding perioperative durvalumab (Imfinzi) to neoadjuvant chemotherapy significantly improved survival outcomes in ...

Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

SOUTH SAN FRANCISCO, Calif., September 19, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), ...